BIOXPEDIA
LIVE

Serial Number

79377424

Owner

BioXpedia A/S

Attorney

Rhett V. Barney

Filing Date

May 30, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BIOXPEDIA Trademark

Serial Number: 79377424 • Registration: 7646444

BIOXPEDIA is a trademark filed by BioXpedia A/S on May 30, 2023. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

BioXpedia A/S

Palle Juul-Jensens Boulevard 82

Entity Type: 99

Trademark Details

Filing Date

May 30, 2023

Registration Date

January 14, 2025

Published for Opposition

November 26, 2024

Goods & Services

Provision of business statistical information relating to medical matters; compilation of statistical data relating to medical research for business purposes; compilation of statistics for business purposes; business assistance, management and administrative services; compilation of medical reports for business purposes

Analytical laboratory services, namely, laboratory research services in the field of biomarker discovery and validation for drug development; scientific and technological services, namely, providing assays and analytical methods for clinical research, drug discovery, and development; research relating to molecular sciences, specifically research involving molecular diagnostics, genomics, and proteomics for personalized medicine; genetic research specifically human genetic research focusing on gene expression profiling, genome-wide association studies, and genetic biomarker discovery; biological analysis; medical and pharmacological research services; biology consultancy; biological research; biological development services specifically development and optimization of biological assays and protocols for preclinical and clinical trials; biochemistry research services; laboratory services specifically for the analysis of proteins, nucleic acids, and small molecules using mass spectrometry, qPCR, ELISA; laboratory services, specifically for the analysis of proteins, nucleic acids, and small molecules using mass spectrometry, qPCR, dPCR, ELISA; biomedical research services; structural and functional analysis of genomes; natural science services, namely, natural science services, namely, scientific research in the fields of biochemistry, molecular biology, and pharmacology; medical research; medical research laboratory services; research in the field of gene therapy, including vector development, gene editing, and delivery mechanisms for therapeutic purposes; scientific research in the field of genetics; laboratory research in the field of gene expression; research in the field of gene editing technology, particularly using CRISPR-Cas9 and other gene-editing tools for therapeutic applications and functional genomics studies; scientific research for medical purposes in the area of cancerous diseases; dna conducting of scientific feasibility studies; DNA screening for scientific research purposes; DNA analysis to determine paternity; research and development services in the field of gene expression systems; analysis of human serum for medical research; analysis of human tissues for medical research; scientific research relating to the isolation and cultivation of human tissues and cells; cell culture services for scientific and research purposes, for others; toxicity analysis, namely, in vitro and in vivo toxicity testing of pharmaceuticals and chemical compounds for safety and efficacy assessments; toxicity testing for scientific research purposes; testing of pharmaceuticals for scientific research; blood analysis services for scientific research purposes

Human healthcare services; medical laboratory analysis services relating to the treatment of persons; medical laboratory services for the analysis of samples taken from patients; medical laboratory services for the analysis of blood samples taken from patients; medical analysis services relating to the treatment of persons provided by a medical laboratory; medical services; medical screening; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical consultations; medical information; medical diagnostic services; medical counseling; providing medical information; issuing of medical reports; genetic testing for medical purposes; medical and health services relating to dna, genetics and genetic testing; medical analysis services for the diagnosis of cancer; DNA screening for medical purposes; RNA and DNA analysis for cancer diagnosis and prognosis for medical purposes; analysis of human serum for medical treatment; medical testing of urine; analysis of human tissues for medical treatment; medical treatment using cultured cells; cultured cell bank services for medical transplantation

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
May 7, 2026 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 8, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 21, 2025 FICS
FINAL DISPOSITION PROCESSED
Jul 21, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 14, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Feb 15, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 27, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 26, 2025 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 14, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 14, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 26, 2024 NPUB
PUBLISHED FOR OPPOSITION
Nov 26, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 20, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 18, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 18, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 18, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 18, 2024 TROA
REFUSAL PROCESSED BY IB
Apr 8, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 19, 2024 RFCS
REFUSAL PROCESSED BY MPU
Mar 19, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 28, 2024 RFCR
NON-FINAL ACTION WRITTEN
Feb 27, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 22, 2024 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Nov 25, 2023 NREP
APPLICATION FILING RECEIPT MAILED
Sep 5, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 1, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 31, 2023 REPR